Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences (NASDAQ: TLSA) has submitted a grant proposal to the UK COVID Therapeutics Advisory Panel to advance the clinical development of Foralumab, an innovative nasal treatment for non-hospitalized COVID-19 patients. This initiative aligns with the UK government's call for at-home therapies. Previous studies in Brazil showed that Foralumab effectively reduced lung inflammation in COVID-19 patients. Additionally, a separate clinical trial for hospitalized patients is in the works. Foralumab could potentially address various COVID-19 variants, enhancing treatment options.
Tiziana Life Sciences has announced that its Notice of Annual General Meeting (AGM) is now available on its website. The AGM is scheduled for June 25, 2021, at 10:00 am BST and will be conducted electronically due to ongoing Covid-19 restrictions. Shareholders are encouraged to submit their proxy votes and any questions in advance to facilitate the meeting. Full details of the AGM procedures are outlined in the Notice of AGM.
Tiziana Life Sciences (NASDAQ: TLSA) announced positive results from its Phase 1 trial of nasally administered Foralumab, showing significant immunomodulatory effects. Conducted at Brigham and Women’s Hospital, the study demonstrated that a 50 mcg/day dose led to favorable changes in cytotoxic T-cell subsets and inflammatory biomarkers without severe toxicity. These findings support further clinical development, primarily targeting progressive MS. Tiziana's innovative approach may enhance treatment outcomes for neurodegenerative diseases.
Tiziana Life Sciences (NASDAQ: TLSA) announced the dosing of the first patient with secondary progressive multiple sclerosis (SPMS) with nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody. The study, conducted at Brigham and Women’s Hospital, focuses on evaluating the treatment's safety, tolerability, and neurological responses over six months. Previous studies indicated Foralumab's well-tolerated nature and strong anti-inflammatory effects, with results showing no significant adverse events. The trial aims to address the urgent need for effective SPMS treatments.
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) announces an interview with CEO Dr. Kunwar Shailubhai, set to air on The RedChip Money Report on May 8, 2021, at 7 p.m. local time. The program reaches approximately 73 million homes via Bloomberg Television. Tiziana focuses on novel therapies in oncology and immunology, with key developments including Foralumab, a unique anti-CD3 monoclonal antibody, and an anti-IL6R monoclonal antibody targeting COVID-19 related inflammation. Caution is advised regarding forward-looking statements.
Tiziana Life Sciences (TLSA) announced a partnership with Takanawa Japan K.K. to find a clinical partner for Milciclib, aimed at treating advanced hepatocellular carcinoma (HCC) in Asia. Milciclib has shown positive results in phase 1 and phase 2 trials, demonstrating tolerability in sorafenib-resistant patients. The partnership focuses on addressing the high prevalence of HCC in Asian countries where treatment options are limited. A recent patent was granted for Milciclib's use in combination therapies, enhancing its development prospects.
Tiziana Life Sciences announced that its CEO Dr. Kunwar Shailubhai and Dr. Howard Weiner will participate in a fireside chat on April 28, 2021, at 10:30 a.m. EDT. The video link session will provide updates on the company's progress, focusing on its innovative therapeutics for oncology and inflammation. Topics will include development efforts for Foralumab and anti-IL6R monoclonal antibodies. No new information will be shared, only data already available publicly. Tiziana is known for its work in treating autoimmune and inflammatory diseases.
On April 13, 2021, Tiziana Life Sciences plc (NASDAQ:TLSA) announced plans for its former subsidiary, Accustem Sciences, to apply for a Nasdaq listing following the distribution of shares to Tiziana's shareholders. The board believes this move aligns better with Accustem's business. Accustem's StemPrintER assay predicts the recurrence risk in R+/HER2- breast cancer patients and has shown superior prognostic capabilities over Oncotype DX. This test aims to refine treatment approaches, helping to identify patients at heightened risk for metastasis.
Tiziana Life Sciences (NASDAQ: TLSA) announced the FDA's approval for evaluating nasal administration of Foralumab in a secondary progressive multiple sclerosis (SPMS) patient at Brigham and Women's Hospital. This marks the first nasal delivery of an antibody for SPMS. The treatment is set to commence in Q2 2021. Prior Phase 1 trials indicated Foralumab's safety for nasal administration. The company aims to address the urgent need for effective treatments in SPMS and has previously reported positive data from COVID-19 studies in Brazil.
Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) has filed a Form 20-F with the SEC to finalize the distribution of shares in Accustem Sciences Limited to its shareholders in the US through the ADS program. This move will separate Accustem as an independent entity, allowing it to pursue its own listing. Shareholders can access detailed information about Accustem via the SEC report linked in the press release.